


Amendments to the Claims

1. (Currently amended) A compound of formula (I):



or pharmaceutically acceptable salts, ~~or solvates, or N₄₀-C₄₄ imine bond prodrugs thereof,~~
 wherein:

R⁶, R⁷ and R⁹ are independently selected from H, R, OH, OR, SH, SR, NH₂, NHR, N[[H]]RR',
 nitro, Me₃Sn and halo;

where R and R' are independently selected from C₁₋₇ alkyl, heterocyclyl having 3 to 20 ring
 atoms of which 1 to 10 are ring heteroatoms independently selected from the group consisting
 N, O and S and aryl or heteroaryl having 5 to 20 ring atoms, the heteroaryl groups having one or
 more heteratoms independently selected from the group consisting of N, O and S;

R⁸ is selected from H, R, OH, OR, SH, SR, NH₂, NHR, N[[H]]RR', nitro, Me₃Sn and halo, or the
 compound is a dimer with each monomer being of formula (I), where the R⁸ groups of each
 monomers form together a dimer bridge having the formula -X-R"-X- linking the monomers,
 where R" is a C₃₋₁₂ alkylene group, which chain may be interrupted by one or more heteroatoms
 selected from the group consisting of O, S, and NH, and/or aromatic rings selected from the
 group consisting of benzene and pyridine, and each X is independently selected from O, S, or
 NH;

or any pair of adjacent groups from R⁶ to R⁹ together form a group -O-(CH₂)_p-O-, where p is 1 or
 2; and

R² is a naphthyl group, optionally substituted by one or more substituents selected from the group
 consisting of halo, C₁₋₇ alkyl, C₁₋₇ alkoxy, heterocyclyl having 3 to 20 ring atoms of which 1 to 10
are ring heteroatoms independently selected from the group consisting N, O and S ~~C₃₋₂₀~~
~~heterocyclyl, C₅₋₂₀ heterocyclyl,~~ and aryl or heteroaryl having 5 to 20 ring atoms, the heteroaryl

groups having one or more heteratoms independently selected from the group consisting of N, O and S₂;

2. Cancelled.

3. Cancelled.

4. (Previously presented) A compound according to claim 1, wherein R⁹ is H.

5. (Previously presented) A compound according to claim 1, wherein R⁶ is H.

6. (Previously presented) A compound according to claim 1, wherein R⁷ and R⁸ (when the compound is not a dimer) are selected from OMe and OCH₂Ph.


7. Cancelled.

8. (Previously presented) A pharmaceutical composition containing a compound of claim 1, and a pharmaceutically acceptable carrier or diluent.

9. Cancelled.

10. (Previously presented) A method of treatment of melanomas, or breast, renal, or lung cancer, comprising administering to a subject in need of treatment a therapeutically-effective amount of a compound of claim 1.

11. (Currently amended) A compound of formula (II)



wherein

R² is a naphthyl group, optionally substituted by one or more substituents selected from the group consisting of halo, C₁₋₇ alkyl, C₁₋₇ alkoxy, heterocyclyl having 3 to 20 ring atoms of which 1 to 10 are ring heteroatoms independently selected from the group consisting N, O and S and aryl or heteroaryl having 5 to 20 ring atoms, the heteroaryl groups having one or more heteratoms independently selected from the group consisting of N, O and S;

R⁶, R⁷ and R⁹ are independently selected from H, R, OH, OR, SH, SR, NH₂, NHR, NRR', nitro, Me₃Sn and halo;

R⁸ is selected from H, R, OH, OR, SH, SR, NH₂, NHR, NRR', nitro, Me₃Sn and halo, or the compound is a dimer with each monomer being of formula (II), where the R⁸ groups of each monomers form together a dimer bridge having the formula -X-R"-X- linking the monomers, where R" is a C₃₋₁₂ alkylene group, which chain may be interrupted by one or more heteroatoms selected from the group consisting of O, S, and NH, and/or aromatic rings selected from the group consisting of benzene and pyridine, and each X is independently selected from O, S, or NH;

or any pair of adjacent groups from R⁶ to R⁹ together form a group -O-(CH₂)_p-O-, where p is 1 or 2;

R₁₀ is selected from:

- (a) 4-NO₂-C₆H₄-CH₂-;
- (b) 2-NO₂-, 4,5-diMeO-C₆H₄-CH₂;
- (c) C₆H₅-CH₂-; and
- (d) Me-SO₂-C₂H₄-;

R₁₁ is selected from OH, OR or SR; and

R and R' are independently selected from C₁₋₇ alkyl, heterocyclyl having 3 to 20 ring atoms of which 1 to 10 are ring heteroatoms independently selected from the group consisting N, O and S and aryl or heteroaryl having 5 to 20 ring atoms, the heteroaryl groups having one or more heteratoms independently selected from the group consisting of N, O and S according to claim 1, wherein the N₄₀-C₄₄ imine bond prodrug comprises a nitrogen protecting group on N₄₀ which can be removed *in vivo* and a hydroxyl, ester or thioester group on C₄₄.

12. Cancelled.